{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:47:08Z","timestamp":1782107228384,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Radiolabeled mass balance human studies are a critical component of clinical pharmacology programs supporting the development of new investigational drugs. These studies provide information about absorption, metabolism, and excretion (AME) of the parent drug and metabolite(s) in the human body and are normally conducted in healthy volunteers (HVs). However, in some instances, based on the characteristics and toxicity of the molecule, conducting the study in HVs may not be a viable option and therefore cancer patients (CPs) need to be enrolled. Successful navigation of aspects such as pharmacologic characteristics, dose administration, patient clinical status and comorbidities, confinement period, study extension, team training, and requirements of the hospitals\/units are essential to successfully deliver radiolabeled mass balance studies in CPs. This article provides an overview of the main aspects that must be taken into consideration to conduct AME studies in CPs.<\/jats:p>","DOI":"10.1111\/cts.70620","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:49:25Z","timestamp":1780062565000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human Absorption, Metabolism, and Excretion (\n                    <scp>hAME<\/scp>\n                    ) Mass Balance Studies in Patients With Cancer"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-1684","authenticated-orcid":false,"given":"Bego\u00f1a de las","family":"Heras","sequence":"first","affiliation":[{"name":"Oncology Consultants  Madrid Spain"},{"name":"Madrid Medical Doctors Association  Madrid Spain"},{"name":"Fortrea Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9089-8225","authenticated-orcid":false,"given":"Claudine","family":"Oelke","sequence":"additional","affiliation":[{"name":"Fortrea Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Atwell","sequence":"additional","affiliation":[{"name":"Fortrea Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3770-8503","authenticated-orcid":false,"given":"Hector","family":"Herrero","sequence":"additional","affiliation":[{"name":"Fortrea Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-9230","authenticated-orcid":false,"given":"Paulo","family":"Nunes","sequence":"additional","affiliation":[{"name":"Fortrea Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6301-3309","authenticated-orcid":false,"given":"Kamal S.","family":"Saini","sequence":"additional","affiliation":[{"name":"Fortrea Inc.  Durham North Carolina USA"},{"name":"Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Vidal","family":"Boixader","sequence":"additional","affiliation":[{"name":"Fortrea Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1768-1322","authenticated-orcid":false,"given":"Catherine","family":"Laing","sequence":"additional","affiliation":[{"name":"Fortrea Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6645-7041","authenticated-orcid":false,"given":"James","family":"Bush","sequence":"additional","affiliation":[{"name":"Fortrea Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-829X","authenticated-orcid":false,"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[{"name":"Director, Clinical Research START Madrid\u2010HM CIOCC Unit, Early Phase Clinical Trials and President, START Europe  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12466"},{"key":"e_1_2_12_3_1","unstructured":"US Food and Drug Administration (FDA) Guidance for Industry \u201cClinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies \u201daccessed September 8 2025 https:\/\/www.fda.gov\/media\/158178\/download."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3040"},{"key":"e_1_2_12_5_1","unstructured":"ClinicalTrials.gov \u201cU.S. National Library of Medicine \u201daccessed September 3 2025 https:\/\/clinicaltrials.gov."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.11.276"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.661"},{"key":"e_1_2_12_8_1","unstructured":"European Medicines Agency (EMA) \u201cGuideline on the Investigation of Drug Interactions. CPMP\/EWP\/560\/95\/Rev. 1 Corr. 2. European Medicines Agency \u201daccessed September 8 2025 https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010investigation\u2010drug\u2010interactions\u2010revision\u20101_en.pdf."},{"key":"e_1_2_12_9_1","volume-title":"Guidance for Industry: Safety Testing of Drug Metabolites","author":"US Food and Drug Administration (FDA)","year":"2008"},{"key":"e_1_2_12_10_1","unstructured":"International Conference on Harmonisation (ICH) \u201cGuidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2) \u201daccessed March 25 2026 https:\/\/database.ich.org\/sites\/default\/files\/M3_R2__Guideline.pdf."},{"key":"e_1_2_12_11_1","unstructured":"European Medicines Agency \u201cICH M3 R2 Q & A May 2012 EMA\/CHMP\/ ICH\/507008\/2011. ICH guideline M3 (R2)\u2014questions and answers \u201daccessed September 11 2025 https:\/\/www.ema.europa.eu\/en\/documents\/other\/international\u2010conference\u2010harmonisation\u2010technical\u2010requirements\u2010registration\u2010pharmaceuticals\u2010_en.pdf."},{"key":"e_1_2_12_12_1","unstructured":"US Food and Drug Administration (FDA) \u201cOncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations. Guidance for Industry \u201daccessed September 11 2025 https:\/\/www.ema.europa.eu\/en\/documents\/other\/international\u2010conference\u2010harmonisation\u2010technical\u2010requirements\u2010registration\u2010pharmaceuticals\u2010_en.pdf."},{"key":"e_1_2_12_13_1","unstructured":"European Medicine Agency (EMA) \u201cConcept Paper on Clinical Evaluation of Therapeutic Radiopharmaceuticals in Oncology. EMA\/CHMP\/451705\/2024 \u201d."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13403"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15092"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967\u2010018\u20101710\u20105"},{"key":"e_1_2_12_17_1","unstructured":"International Council for Harmonisation (ICH) \u201cSafety Pharmacology Studies for Human Pharmaceuticals. ICH S7A Guideline \u201daccessed September 9 2025 https:\/\/database.ich.org\/sites\/default\/files\/S7A_Guideline.pdf."},{"key":"e_1_2_12_18_1","unstructured":"International Council for Harmonisation (ICH) \u201cGuidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. ICH S2(R1) Guideline \u201daccessed September 10 2025 https:\/\/database.ich.org\/sites\/default\/files\/S2_R1_Guideline.pdf."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15256"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-2999-5"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0321-8"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00815-2"},{"key":"e_1_2_12_23_1","unstructured":"European Medicinal Agency (EMA) \u201cNiraparib summary of product characteristics. Zejula (INN\u2013niraparib) \u201daccessed April 16 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/zejula\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_12_24_1","unstructured":"Food and Drug Administration (FDA) \u201cNiraparib prescribing information \u201daccessed April 16 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214876s000lbl.pdf."},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0451-2"},{"key":"e_1_2_12_26_1","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA) \u201cManufacture of Investigational Medicinal Products: Frequently Asked Questions. MHRA Inspectorate Blog \u201daccessed April 22 2025 https:\/\/mhrainspectorate.blog.gov.uk\/2023\/02\/03\/manufacture\u2010of\u2010investigational\u2010medicinal\u2010products\u2010frequently\u2010asked\u2010questions."},{"key":"e_1_2_12_27_1","unstructured":"European Commission \u201cEudraLex\u2010 Volume 4 EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use \u201daccessed September 1 2008 https:\/\/health.ec.europa.eu\/medicinal\u2010products\/eudralex\/eudralex\u2010volume\u20104_en."},{"key":"e_1_2_12_28_1","unstructured":"International Council for Harmonised Tripartite Guideline \u201cGood Manufacturing Practice Guide for Active Pharmaceutical Ingredients Current Step 4 version. Q7 Section\u00a019 pages 37\u201338 \u201daccessed November 10 2000 https:\/\/database.ich.org\/sites\/default\/files\/Q7_Guideline.pdf."},{"key":"e_1_2_12_29_1","unstructured":"United States Food and Drug Administration \u201cCode of Federal Regulations 21 CFR: Part 361.1 Radioactive Drugs for Certain Research Uses \u201dhttps:\/\/www.ecfr.gov\/current\/title\u201021\/chapter\u2010I\/subchapter\u2010D\/part\u2010361\/section\u2010361.1."},{"key":"e_1_2_12_30_1","unstructured":"United States Pharmacopeia \u201cGeneral Chapter\u00a0797 Pharmaceutical Compounding\u2014Sterile Preparations \u201dhttps:\/\/www.usp.org\/compounding\/general\u2010chapter\u2010797."},{"key":"e_1_2_12_31_1","unstructured":"US Food and Drug Administration (FDA) Guidance for Industry \u201cGood Review Practice: Clinical Review of Investigational New Drug Applications \u201daccessed September 9 2025 https:\/\/www.fda.gov\/media\/87621\/download."},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555\u2010025\u201010253\u20107"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42462"},{"key":"e_1_2_12_34_1","first-page":"1052","article-title":"Polypharmacy, Aging, and Cancer","volume":"22","author":"Tam\u2010McDevitt J.","year":"2008","journal-title":"Oncology (Williston Park, N.Y.)"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.0579"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70620","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:53:13Z","timestamp":1782103993000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/cts.70620"],"URL":"https:\/\/doi.org\/10.1111\/cts.70620","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2026-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70620"}}